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Abstract
Introduction: Dipeptidil peptidase 4 inhibitors (DPP-4) are a group of antihyperglycemic agents. DPP-4 is an enzyme expressed on lym-
phocyte surface as co-stimulatory molecule in activation processes. The aim was to assess lymphocyte subpopulations initially and after 
14 days of treatment with DPP-4 inhibitors sitagliptin, saxagliptin and vildagliptin. 
Material and methods: The study was conducted in three groups 10 subjects each, of type 2 diabetic patients. In subjects studied an initial 
tests followed by repeated ones after 14 days of treatment with sitagliptin, saxagliptin, and vildagliptin in therapeutic doses were per-
formed. Baseline test as well as lymphocyte subpopulations (total T cells, and T-cell subsets CD4+, CD8+, CD26+, CD45RA+, CD45RO+, 
CD4+/CD25+) using 7-colour flow cytometry method were performed. 
Results: In patients receiving sitagliptin no significant increase in lymphocyte subpopulations were observed. In patients who received 
vildagliptin significant increase of total T-cells (p < 0.05); in patients treated with saxagliptin significant (p < 0.05) though mild increased 
percentage of total T-cells and CD4+, CD26+, CD45RO+ subsets were found. 
Conclusions: The study showed mild but significant increase of several T-cell subsets after treatment with saxagliptin and vildagliptin 
with non significant elevation after treatment with sitagliptin. It seems that changes are not expressed enough to have a clinical impact. 
(Endokrynol Pol 2014; 65 (2): 78–82)
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Streszczenie
Wstęp: Inhibitory dipeptydylo peptydazy 4 (DPP-4) są nową grupą leków hipoglikemizujących. DPP-4 jest enzymem występującym mię-
dzy innymi na powierzchni limfocytów, molekułą ko-stymulującą w procesach aktywacji. Celem niniejszej pracy była ocena subpopulacji 
limfocytów przed i po 14-dniowym leczeniu inhibitorami DPP-4 sitagliptyną, saxagliptyną i vildagliptyną.
Materiał i metody: Badanie przeprowadzono w trzech 10-osobowych grupach pacjentów z cukrzycą typu 2. U badanych wykonano 
badania wstępne, a następnie badania powtórzono po 14 dniach pobierania sita-, saxa- i vildagliptyny w dawkach terapeutycznych. 
U badanych wykonano badania podstawowe, a także oznaczono subpopulacje limfocytów (całkowite limfocyty T oraz subpopulacje 
limfocytów T CD4+, CD8+, CD26+, CD45RA+, CD45RO+, CD4+/CD25+; całkowite limfocyty B i subpopulacja CD26+) metodą 7-ko-
lorowej cytometrii przepływowej.
Wyniki: U badanych otrzymujących sitagliptynę nie obserwowano znamiennego wzrostu w zakresie badanych subpopulacji limfocytów. 
U chorych otrzymujących vildagliptynę obserwowano istotny (p < 0,05), choć niewielki wzrost całkowitej puli limfocytów. Pacjenci otrzy-
mujący saxagliptynę wykazywali istotny (p < 0.05), choć niewielki wzrost odsetka limfocytów T całkowitych, TCD4, CD26+, CD45RO+.
Wnioski: Badanie wskazuje na niewielki wzrost puli limfocytów T po zastosowaniu saxagliptyny i vildagliptyny, bez wpływu sita-
gliptyny. Wydaje się, ze stwierdzane zmiany, mimo że znamienne, są na tyle niewielkie, że nie powinny mieć znaczenia klinicznego. 
(Endokrynol Pol 2014; 65 (2): 78–82)
Słowa kluczowe: cukrzyca typu 2; inhibitory DPP-4; subpopulacje limfocytów
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Introduction
Diabetes is a serious medical and social problem [1]. 
The number of patients is increasing, and thus so is 
the number of patients affected by late complications 
[2]. There is therefore a need to seek new forms of 
therapy, which could reduce the risk of developing 
complications by improving metabolic control. Dipep-
tidyl peptidase-4 inhibitors (DPP-4) are a new group 
of anti-hyperglycaemic drugs whose mechanism of 
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action consists of the inhibition of degradation of 
glucagon-like peptide 1 (GLP1) and thus increasing 
its concentration, resulting in increased glycaemic 
stimulus-induced insulin release [3, 4]. Numerous 
clinical studies have documented the hypoglycaemic 
efficacy of these drugs, both as monotherapy and 
combination therapy [5, 6]. The use of drugs from this 
group allows the reduction of HbA1c by 0.6–0.8% [7]. 
DPP-4, also known as CD-26, is an enzyme present 
on the surface of most cell types, as well as on those 
circulating in the blood. It decomposes peptides con-
taining proline or alanine; in addition to GLP-1, these 
are various growth factors, chemokines, cytokines, 
neuropeptides [8]. It has been reported that patients 
with type 2 diabetes have a reduced expression of 
CD26 on lymphocytes compared to healthy subjects; 
moreover, the expression of surface CD26 has been 
shown to be negatively correlated with DPP-IV activ-
ity in the lymphocytes [9].
CD26/DPP-4 has many physiological effects, includ-
ing immune regulation, as a molecule transmitting 
co-stimulatory signals in T-cell activation processes [10, 
11]. In vitro studies have shown to affect the immune 
system, associated with shifts in the lymphocyte pool 
[12]. Clinical observations have shown that the use of 
DPP4 inhibitors may increase the risk of infections, 
especially nasal-pharyngeal [5, 13]. 
Therefore, the question arises as to what extent the 
use of DPP-4 inhibitors in routine clinical practice may 
modify the immune system? 
Such analysis has not been performed in an in 
vivo study so far. Since CD26/DPP-4 is expressed on a 
subset of normal lymphocytes, we hypothesised that 
the application of DPP-4 inhibitors might influence 
the composition of lymphocyte compartment and 
their function. To support our assumption, there is 
evidence showing clinical improvement of patients 
with autoimmune diseases after treatment with 
DPP-4 inhibitors. [14]. In contrast, in diabetic patients 
treated with sitagliptin, there was no effect on CD4+ 
T-cell activation [15].
The aim of this study was to evaluate selected lym-
phocyte subpopulations before and after 14 days of 
treatment in three groups of patients receiving thera-
peutic doses of saxagliptin, sitagliptin and vildagliptin. 
Material and methods
This study was conducted on a group of 30 patients 
selected according to the following criteria: type 2 
diabetes treated with insulin in monotherapy with-
out other hypoglycaemic agents, no clinical signs 
of infection on clinical examination, normal levels 
of inflammatory markers (CRP and IL-6), no signs 
of liver damage (ALT < 2 x ULN), and no signs of 
nephropathy (GFR > 90 mL/min/1.73 m2). Patients 
with known contraindications for DPP-4 inhibitors, 
as well as immunocompromised or allergic subjects, 
were excluded.
The patients were randomly divided into three 
groups, consisting of ten persons each. Each group 
received saxagliptin, sitagliptin or vildagliptin respec-
tively in therapeutic doses as indicated in diabetes 
management, in addition to the current insulin therapy. 
During the study, the insulin dose was titrated ac-
cording to blood glucose levels. The characteristics of 
the study groups are shown in Table I. No significant 
differences between the groups were observed. The 
study was approved by the Bioethics Committee at the 
Medical University of Silesia. 
The study was conducted in an inpatient setting. 
All subjects were screened and blood was collected for 
baseline analyses, then the study drug was added to the 
current antidiabetic therapy — saxagliptin, sitagliptin 
or vildagliptin respectively. After 14 days of treatment, 
blood was collected again for tests. The following as-
sessments were performed: 
 — anthropometric measurements (body weight, height);
 — HbA1c — using the HPLC method;
 — fasting blood glucose — using the immunoenzy-
matic method.
Immunophenotyping of each sample was per-
formed using the 7-colour flow cytometry on a BD 
FACSCantoII flow cytometer. Each time, 2 mL of blood 
was collected on anticoagulant (EDTA) by peripheral 
vein puncture, then the sample was analysed within 
two hours of collection. 
Samples were analysed using a computer program 
DIVA (Becton Dickinson Biosciences, San Jose, CA, 
USA). The method of whole blood typing with sub-
sequent RBC lysis was used. In order to determine 
individual lymphocyte subpopulations, a panel of nine 
Table I. Study group characteristics. Data presented as means 
± SD
Tabela I. Charakterystyka badanych grup. Dane przedstawiono 
jako średnie ± SD
Saxagliptin 
(n = 10)
Sitagliptin 
(n = 10)
Vildagliptin 
(n = 10)
Age (years) 61 ± 17 60 ± 11 57 ± 9
Sex M/F 3/7 3/7 6/4
Duration (years) 15 ± 9 15 ± 13 9 ± 6
BMI [kg/m2] 33.9 ± 4.9 30.8 ± 11.9 31.9 ± 13.8
HbA1c (%) 9.5 ± 1.1 8.7 ± 1.2 9.5 ± 1.7
Insulin dose [IU/kg] 0.97 ± 0.31 0.69 ± 0.47 0.70 ± 0.25
BMI — body mass index; NS
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monoclonal antibodies was used, in accordance with 
the standard staining protocol [16, 17]. The combina-
tions of antibodies used in the diagnostic panel are 
shown in Table II.
Results
The results for T-lymphocyte subpopulations are shown 
in Table III, and Figure 1 illustrates an example distribu-
tion of lymphocyte subpopulations. 
A small, significant increase in T-lymphocyte per-
centage was shown after 14 days of using saxagliptin 
and vildagliptin (p < 0.05), with no significant change 
with sitagliptin. In patients treated with saxagliptin, 
a significant increase of helper T-cells (CD4+) with 
memory cell phenotype (CD45RO+; p < 0.05) was 
found. In addition, the use of saxagliptin was associ-
ated with an increase in T-cells showing CD26 expres-
sion (p < 0.05). There were no changes in the pool of 
suppressor-cytotoxic T-cells (CD8+) and the population 
of T-cells containing regulatory cells (CD4+/CD25+).
There were no changes in the percentage of B-cells 
including the small subpopulation of B-cells express-
ing CD26.
Discussion
This study demonstrated that 14-day use of saxaglip-
tin and vildagliptin resulted in a significant, albeit 
slim, increase in the entire T-cell population. A non 
significant increase was observed in patients receiv-
ing sitagliptin. Additionally, in patients receiving 
saxagliptin helper T-cells expressing the phenotype of 
memory cells were found. At the same time, there was 
an increase in the subpopulation of T-lymphocytes 
expressing CD26 antigen. One would expect that 
the inhibition of DPP-4 decreases the proportion of 
CD26-expressing lymphocytes in peripheral blood. 
What we observed was the complete opposite. Thus, 
inhibition of DPP-4 stimulates increase in CD26+ 
lymphocytes most probably to compensate in this 
way the inhibitory effect of the drug.
The study was conducted in type 2 diabetics treated 
initially with insulin only. We selected such a group of 
subjects because the aim was to analyse the lymphocyte 
subpopulation but not the antihyperglycaemic effect 
of DPP-4 inhibitors. Thus we decided not to include 
patients treated with oral drugs to avoid potential 
interactions. 
Table II. Monoclonal antibody panel for lymphocyte subpopulation assessment
Tabela II. Panel przeciwciał monoklonalnych do oceny subpopulacji limfocytów
No. FITC PE PerCP PE-Cy7 APC APC-Cy7 Pacific Blue
1. CD45RO
Dako
CD26
BD
CD3  
BD
CD45RA 
BD 
CD25 BD CD8  
BD
CD4  
Biolegend
2. CD26
BD
CD3  
BD
CD19  
BC
Monoclonal antibodies used in the study: BD — Becton Dickinson, San Jose, CA, USA; BC — Beckman Coulter; Dako — Dakopatts, Glostrup, 
Denmark; FITC — fluorescein isothiocyanate; PE — phycoerythrin; PerCP — peridinin-chlorophyll; PE-Cy7 — phycoerythrin-cyanine 7; APC 
— allophycocyanin; APC-Cy7 — allophycocyanin-cyanine 7
Table III. Subpopulations of studied T-lymphocytes in groups of patients receiving saxagliptin, sitagliptin and vildagliptin 
before and after 14 days of treatment. Data presented as mean percentages ± SD of total lymphocyte population
Tabela III. Subpopulacje badanych limfocytów T w grupach chorych pobierających saxagliptynę, sitagliptynę, i vildagliptynę 
przed i po 14 dniach leczenia. Dane przedstawiono jako średnie ± SD odsetków populacji limfocytów
Total 
T-lymphocytes
T-lymphocytes 
CD4+
T-lymphocytes 
CD8+
T-lymphocytes 
CD26+
T-lymphocytes 
CD45RA+
T-lymphocytes 
CD45RO+
T-lymphocytes 
CD4+/CD25+
Sitagliptin Before 69.2 ± 5.5 45.0 ± 7.3 19.9 ± 8.1 54.0 ± 7.5 25.3 ± 8.7 38.1 ± 7.7 23.5 ± 4.7
After 69.6 ± 6.9 45.9 ± 7.8 19.7 ± 7.1 55 ± 12.3 26.0 ± 7.6 39.2 ± 10.3 22.6 ± 8.3
Saxagliptin Before 69.2 ± 9.4 42.7 ± 6.8 22.6 ± 6.1 51.1 ± 9.1 30.1 ± 10.6 35.7 ± 6.5 19.9 ± 5.1
After 72.8 ± 7.8* 45.4 ± 6.9* 23.1 ± 5.3 54.6 ± 10.1* 30.5 ± 10.6 38.3 ± 6.5* 17.8 ± 4.4
Vildagliptin Before 66.9 ± 5.1 42.2 ± 7.8 21.1 ± 6.2 45.5 ± 7.2 26.1 ± 7.7 35.7 ± 4.7 17.3 ± 8.1
After 70.1 ± 3.9* 44.2 ± 9.5 19.7 ± 8.3 48.2 ± 8.4 25.2 ± 7.9 38.6 ± 8.5 17.8 ± 10.7
*p < 0.05 v. baseline value
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In humans, CD26/DPP4 appears late in the differ-
entiation of T-cells in the thymus, and is preferentially 
restricted to a subpopulation of helper/memory cells 
[16]. CD26/DPP4 plays a role of co-stimulator in the 
processes of activation. CD26 expression is the high-
est in CD4+ T-cells, which produce, among other 
substances, IL-22, IL-17, GM-CSF or TNF (Th17 cells), 
playing a key role in inflammatory reactions in the 
body [19]. The presented results indicate that DPP4 
inhibition causes a discrete increase in the percentage 
of these populations. 
In the literature, we found a single report on the ef-
fect of DPP4 inhibitors on T-cell subpopulations. White 
et al. evaluated CD4+ lymphocyte subpopulations in 
two groups of 20 patients receiving sitagliptin for half 
a year, or treated with other groups of hypoglycaemic 
drugs. These authors found no differences between 
the study groups [15]. Our study adds new elements of 
knowledge. Lymphocyte subpopulations were analysed 
before and after 14 days of treatment with drugs studied 
in the same group of patients. In addition, the study was 
extended to additional subpopulations of lymphocytes. 
Our results confirm the data obtained by the above-cited 
authors for sitagliptin. However, they suggest a signifi-
cant, albeit small, effect of saxagliptin and vildagliptin, 
and non significant influence of sitagliptin. A similarly 
increasing trend in lymphocytes subpopulations of each 
drug suggests that it is a group effect rather than the 
influence of a particular drug. 
Conclusion
The present study showed a minor increase in the lym-
phocyte content after treatment with DPP-4 inhibitors. 
It seems that the observed changes are so discrete that 
they might not have clinical relevance. 
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